Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia

Hematological Oncology

Volumn 27, Issue 4, 2009, Pages 198-202

  Ferrara, Felicetto ^a   Mele, Giuseppina ^a   Palmieri, Salvatore ^a   Pedata, Mariangela ^a   Copia, Carolina ^a   Riccardi, Cira ^a   Izzo, Tiziana ^a   Criscuolo, Clelia ^a   Musto, Pellegrino ^b  

^a CARDARELLI HOSPITAL   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

Author keywords

Acute myeloid leukaemia; Autologous transplantation; Conditioning regimen; Idarubicin; Intravenous busulphan

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUSULFAN; CIPROFLOXACIN; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PHENYTOIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOIMMUNIZATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BLOOD TRANSFUSION; CD34 SELECTION; CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HOSPITALIZATION; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SEIZURE; STOMATITIS; THROMBOCYTE COUNT; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; ADOLESCENT; AUTOTRANSPLANTATION; CLINICAL TRIAL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IDARUBICIN; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 73349115857     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.903     Document Type: Article

References (31)

1. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant 2008; 14: 556-567.
2. Kolitz JE. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 2006; 134: 555-572.
3. Linker C. The role of autologous transplantation for acute myeloid leukemia in first and second remission. Best Pract Res Clin Haematol 2007; 20: 77-84.
4. Breems DA, Löwenberg B. Acute myeloid leukemia and the position of autologous stem cell transplantation. Semin Hematol 2007; 44: 259-266.
5. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf 2008; 3: 60-66.
6. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol 2007; 2: 75-91.
7. Cho YH, Lim HA, Lee MH et al. Pharmacokinetics and tolerability of intravenous busulfan in hematopoietic stem cell transplantation. Clin Transplant 2007; 21: 417-422.
8. Aschan J. Risk assessment in haematopoietic stem cell transplantation: conditioning. Best Pract Res Clin Haematol 2007: 295-310.
9. Bartelink IH, Bredius RG, Ververs TT, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 88-98.
10. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007l; 13: 814-821.
11. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006; 12: 770-777.
12. Kim JG, Sohn SK, Chae YS, et al., Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007; 40(10): 919-924.
13. Ferrara F, Palmieri S, Desimone M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol 2005; 128: 234-241.
14. Ferrara F, Palmieri S, Annunziata M, et al. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation. Bone Marrow Transplant 2004; 34: 573-576.
15. Vardiman JW, Harris N, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
16. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 2000; 18: 1295-1300.
17. ISCN. Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature Mitelman F (ed.). S Karger: Basel, 1995.
18. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 1998; 92: 2322-2333.
19. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-1320.
20. Ferrara F, Palmieri S, Pollio F, et al. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia. Biol Blood Marrow Transplant 2006; 12: 981-986.
21. Ferrara F, D'arco AM, Desimone MC, et al. Fludarabine and cytarabine as continuous sequential infusion for elderly patients with acute myeloid leukemia. Haematologica 2005; 90: 776-784.
22. WHO handbook for reporting results of cancer treatment. World Health Organization, Geneva 38: 1979.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
24. Gorin NC, Labopin M, Pichard P, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol 2000; 110: 887-893.
25. Ferrara F. Unanswered questions in acute myeloid leukaemia. Lancet Oncol 2004; 5: 443-450.
26. Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008; 26: 4944-4951.
27. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute non lymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
28. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1983; 70: 1382-1388.
29. Meloni G, Vignetti M, Avvisati G, et al. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 1996; 18: 693-698.
30. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 2002; 29: 297-301.
31. Tallman MS, Pérez WS, Lazarus HM, et al. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2006; 12: 204-216.